Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.57 |
| ▸ | F2 | P00734 | 2/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15857721 | 1.00 | F10 (0.57) | F10F2ABCB11ST14 | |
| SCHEMBL76883 | 0.80 | F10 (0.59) | F10F2ABCB11ST14 | |
| SCHEMBL946532 | 0.80 | F10 (0.59) | F10F2ABCB11ST14 | |
| SCHEMBL17588942 | 0.79 | F10 (0.58) | F10F2ABCB11ST14 | |
| SCHEMBL20618506 | 0.74 | HDAC3 (0.58) | F10F2 | |
| SCHEMBL8257548 | 0.73 | F10 (0.47) | F10F2 | |
| SCHEMBL24177659 | 0.73 | F10 (1.00) | F10F2ABCB11ST14 | |
| SCHEMBL13698655 | 0.73 | F10 (1.00) | F10F2ABCB11ST14 | |
| SCHEMBL77589 | 0.73 | F10 (1.00) | F10F2ABCB11ST14 | |
| SCHEMBL8259083 | 0.73 | MAPK1 (0.47) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160301-A1 | MICROANGIOPATHY TREATMENT AND PREVENTION | BAYER HEALTHCARE AG | 2010-06-24 | — | — | US | disclosed |
| US-7592339-B2 | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-09-22 | — | — | US | disclosed |
| US-20060258724-A1 | Substituted Oxazolidinones and Their Use in the Field of Blood Coagulation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-11-16 | — | — | US | disclosed |
| WO-2003000256-A1 | SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY | BAYER HEALTHCARE AG (DE) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160301-A1 | MICROANGIOPATHY TREATMENT AND PREVENTION | SERPINC1, TFPI, F11 | F10 10/4885F2 35/4885ABCB11 3613/4885 |
| US-20060258724-A1 | Substituted Oxazolidinones and Their Use in the Field of Blood Coagulation | F2, F11, F13B | F10 9/4885F2 1/4885ABCB11 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.